tiprankstipranks
Beam Therapeutics, Inc. (MX:BEAM)
NASDAQ:BEAM
Mexico Market
BEAM
Beam Therapeutics
RESEARCH TOOLSreports

Beam Therapeutics (BEAM) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

BEAM Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Beam
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BEAM Stock 12 Month Forecast

Average Price Target

$926.38
Based on 11 Wall Street analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $926.38 with a high forecast of $1,400.71 and a low forecast of $455.23. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"324":"$324","1401":"$1,401","593.25":"$593.3","862.5":"$862.5","1131.75":"$1,131.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1400.7073576,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.40K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":926.3769115036362,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$926.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":455.22989122,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$455.23</span>\n  </div></div>","useHTML":true}}],"tickPositions":[324,593.25,862.5,1131.75,1401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,628.46,687.8636428923078,747.2672857846154,806.6709286769232,866.0745715692308,925.4782144615385,984.8818573538463,1044.2855002461538,1103.6891431384615,1163.0927860307693,1222.496428923077,1281.9000718153848,1341.3037147076925,{"y":1400.7073576,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,628.46,651.3766855002798,674.2933710005594,697.2100565008392,720.1267420011188,743.0434275013986,765.9601130016782,788.876798501958,811.7934840022376,834.7101695025174,857.626855002797,880.5435405030768,903.4602260033564,{"y":926.3769115036362,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,628.46,615.1346070169232,601.8092140338462,588.4838210507693,575.1584280676923,561.8330350846154,548.5076421015385,535.1822491184615,521.8568561353846,508.5314631523077,495.20607016923077,481.8806771861539,468.5552842030769,{"y":455.22989122,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":330,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":383,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":475,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":485,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":604,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":520,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":520,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":525,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":564.61,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":628.46,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,401Average Price Target$926.38Lowest Price Target$455.23
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on MX:BEAM
Alec Stranahan
Bank of America Securities
Bank of America Securities
$822.92
Buy
―
Reiterated
07/08/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Encompass Health (NYSE: EHC) and Annexon Biosciences (NASDAQ: ANNX)
H.C. Wainwright Analyst forecast on MX:BEAM
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$1,400.71
Buy
―
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (NASDAQ: LENZ), Novavax (NASDAQ: NVAX) and Beam Therapeutics (NASDAQ: BEAM)
Wedbush Analyst forecast on MX:BEAM
David Nierengarten
Wedbush
Wedbush
$1,138.07
Buy
―
Reiterated
06/22/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Beam Therapeutics (BEAM)
Wells Fargo Analyst forecast on MX:BEAM
Yanan Zhu
Wells Fargo
Wells Fargo
$1,225.62
Buy
―
Reiterated
06/04/26
Wells Fargo Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
Canaccord Genuity Analyst forecast on MX:BEAM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$1,313.16
Buy
―
Reiterated
05/21/26
Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity
Citi Analyst forecast on MX:BEAM
Samantha Semenkow
Citi
Citi
$1,190.6
Buy
―
Reiterated
05/13/26
Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged
Bernstein Analyst forecast on MX:BEAM
William Pickering
Bernstein
Bernstein
$700.35→$682.84
Buy
―
Assigned
05/13/26
Beam Therapeutics price target lowered to $39 from $40 at BernsteinBeam Therapeutics price target lowered to $39 from $40 at Bernstein
Evercore ISI Analyst forecast on MX:BEAM
Cory Kasimov
Evercore ISI
Evercore ISI
$612.81→$787.9
Buy
―
Reiterated
05/08/26
Evercore ISI Sticks to Their Buy Rating for Beam Therapeutics (BEAM)
RBC Capital Analyst forecast on MX:BEAM
Luca Issi
RBC Capital
RBC Capital
$455.23
Hold
―
Reiterated
05/08/26
Analysts Conflicted on These Healthcare Names: Monte Rosa Therapeutics (NASDAQ: GLUE) and Beam Therapeutics (NASDAQ: BEAM)
JonesTrading Analyst forecast on MX:BEAM
Boris Peaker
JonesTrading
JonesTrading
$612.81
Buy
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (NASDAQ: TRDA) and Beam Therapeutics (NASDAQ: BEAM)
William Blair Analyst forecast on MX:BEAM
Sami Corwin
William Blair
William Blair
$560.28
Buy
―
Reiterated
05/07/26
Analysts' Top Healthcare Picks: Bioventus (BVS), Insmed (INSM)
J.P. Morgan Analyst forecast on MX:BEAM
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
03/25/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Maze Therapeutics, Inc. (NASDAQ: MAZE) and Daiichi Sankyo Company (Other OTC: DSKYF)
Clear Street Analyst forecast on MX:BEAM
William Maughan
Clear Street
Clear Street
$647.83
Buy
―
Reiterated
03/25/26
Clear Street sees buying opportunity for Beam Therapeutics after study updateClear Street sees buying opportunity for Beam Therapeutics after study update
UBS Analyst forecast on MX:BEAM
Michael Yee
UBS
UBS
$490.25
Hold
―
Initiated
01/06/26
Beam Therapeutics initiated with a Neutral at UBSBeam Therapeutics initiated with a Neutral at UBS
Barclays Analyst forecast on MX:BEAM
Gena Wang
Barclays
Barclays
$367.69
Hold
―
Reiterated
11/05/25
Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bank of America Securities Analyst forecast on MX:BEAM
Alec Stranahan
Bank of America Securities
Bank of America Securities
$822.92
Buy
―
Reiterated
07/08/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Encompass Health (NYSE: EHC) and Annexon Biosciences (NASDAQ: ANNX)
H.C. Wainwright Analyst forecast on MX:BEAM
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$1,400.71
Buy
―
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (NASDAQ: LENZ), Novavax (NASDAQ: NVAX) and Beam Therapeutics (NASDAQ: BEAM)
Wedbush Analyst forecast on MX:BEAM
David Nierengarten
Wedbush
Wedbush
$1,138.07
Buy
―
Reiterated
06/22/26
Analysts Are Bullish on Top Healthcare Stocks: AbbVie (ABBV), Beam Therapeutics (BEAM)
Wells Fargo Analyst forecast on MX:BEAM
Yanan Zhu
Wells Fargo
Wells Fargo
$1,225.62
Buy
―
Reiterated
06/04/26
Wells Fargo Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
Canaccord Genuity Analyst forecast on MX:BEAM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$1,313.16
Buy
―
Reiterated
05/21/26
Beam Therapeutics (BEAM) Gets a Buy from Canaccord Genuity
Citi Analyst forecast on MX:BEAM
Samantha Semenkow
Citi
Citi
$1,190.6
Buy
―
Reiterated
05/13/26
Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged
Bernstein Analyst forecast on MX:BEAM
William Pickering
Bernstein
Bernstein
$700.35→$682.84
Buy
―
Assigned
05/13/26
Beam Therapeutics price target lowered to $39 from $40 at BernsteinBeam Therapeutics price target lowered to $39 from $40 at Bernstein
Evercore ISI Analyst forecast on MX:BEAM
Cory Kasimov
Evercore ISI
Evercore ISI
$612.81→$787.9
Buy
―
Reiterated
05/08/26
Evercore ISI Sticks to Their Buy Rating for Beam Therapeutics (BEAM)
RBC Capital Analyst forecast on MX:BEAM
Luca Issi
RBC Capital
RBC Capital
$455.23
Hold
―
Reiterated
05/08/26
Analysts Conflicted on These Healthcare Names: Monte Rosa Therapeutics (NASDAQ: GLUE) and Beam Therapeutics (NASDAQ: BEAM)
JonesTrading Analyst forecast on MX:BEAM
Boris Peaker
JonesTrading
JonesTrading
$612.81
Buy
―
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (NASDAQ: TRDA) and Beam Therapeutics (NASDAQ: BEAM)
William Blair Analyst forecast on MX:BEAM
Sami Corwin
William Blair
William Blair
$560.28
Buy
―
Reiterated
05/07/26
Analysts' Top Healthcare Picks: Bioventus (BVS), Insmed (INSM)
J.P. Morgan Analyst forecast on MX:BEAM
Brian Cheng
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
03/25/26
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (NASDAQ: BEAM), Maze Therapeutics, Inc. (NASDAQ: MAZE) and Daiichi Sankyo Company (Other OTC: DSKYF)
Clear Street Analyst forecast on MX:BEAM
William Maughan
Clear Street
Clear Street
$647.83
Buy
―
Reiterated
03/25/26
Clear Street sees buying opportunity for Beam Therapeutics after study updateClear Street sees buying opportunity for Beam Therapeutics after study update
UBS Analyst forecast on MX:BEAM
Michael Yee
UBS
UBS
$490.25
Hold
―
Initiated
01/06/26
Beam Therapeutics initiated with a Neutral at UBSBeam Therapeutics initiated with a Neutral at UBS
Barclays Analyst forecast on MX:BEAM
Gena Wang
Barclays
Barclays
$367.69
Hold
―
Reiterated
11/05/25
Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
ENOVEnovis
GKOSGlaukos
IFRXInflaRx
BKDBrookdale Senior Living
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Beam Therapeutics

3 Months
Patrick TrucchioH.C. Wainwright
Success Rate
13/20 ratings generated profit
65%
Average Return
+0.64%
Copying Patrick Trucchio's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +0.64% per trade.
1 Year
Alec StranahanBank of America Securities
Success Rate
7/14 ratings generated profit
50%
Average Return
+18.91%
Copying Alec Stranahan's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +18.91% per trade.
2 Years
Alec StranahanBank of America Securities
Success Rate
8/14 ratings generated profit
57%
Average Return
+14.02%
Copying Alec Stranahan's trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +14.02% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BEAM Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
18
17
19
10
9
Buy
19
11
10
6
6
Hold
2
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
39
29
30
17
16
In the current month, BEAM has received 15 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BEAM average Analyst price target in the past 3 months is 926.38.
Each month's total comprises the sum of three months' worth of ratings.

BEAM Financial Forecast

BEAM Earnings Forecast

Next quarter’s earnings estimate for BEAM is -$19.36 with a range of -$21.71 to -$16.67. The previous quarter’s EPS was -$15.93. BEAM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.
Next quarter’s earnings estimate for BEAM is -$19.36 with a range of -$21.71 to -$16.67. The previous quarter’s EPS was -$15.93. BEAM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.

BEAM Sales Forecast

Next quarter’s sales forecast for BEAM is $286.62M with a range of $0.00 to $583.04M. The previous quarter’s sales results were $555.70M. BEAM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.
Next quarter’s sales forecast for BEAM is $286.62M with a range of $0.00 to $583.04M. The previous quarter’s sales results were $555.70M. BEAM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.

BEAM Stock Forecast FAQ

What is MX:BEAM’s average 12-month price target, according to analysts?
Based on analyst ratings, Beam Therapeutics, Inc.’s 12-month average price target is 926.38.
    What is MX:BEAM’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:BEAM, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Beam Therapeutics, Inc. a Buy, Sell or Hold?
        Beam Therapeutics, Inc. has a consensus rating of Strong Buy, which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Beam Therapeutics, Inc.’s share price target?
          The average share price target for Beam Therapeutics, Inc. is 926.38. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $1,400.71 ,and the lowest forecast is $455.23. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Beam Therapeutics, Inc.?
            Beam Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
              How can I buy shares of Beam Therapeutics, Inc.?
              To buy shares of MX:BEAM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.